Drug intelligence / Profile preview

FLAG Therapeutics AAT inhibitor

Development stage: Preclinical
Lead developer: FLAG Therapeutics
Modality: Small Molecules

Overview

FLAG Therapeutics AAT inhibitor is an undisclosed small molecule designed to inhibit alpha-1 antitrypsin (AAT). Developed by FLAG Therapeutics, this compound is being investigated for the treatment of Triple Negative Breast Cancer (TNBC) and Lewy Body Dementia (LBD). While AAT is traditionally recognized as a protective serine protease inhibitor (serpin) in the context of lung and liver health, FLAG Therapeutics is exploring its inhibition as a novel therapeutic strategy to address the underlying pathology in specific aggressive cancers and neurodegenerative disorders.

Other names: AAT inhibitor (FLAG Therapeutics)Alpha-1 antitrypsin inhibitor (FLAG Therapeutics)

Targets

SERPINA1 (Alpha-1-antitrypsin)

Beyond the preview

Go deeper on FLAG Therapeutics AAT inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLAG Therapeutics AAT inhibitor.

Explore the full profile